Spit test could predict drug response in rare lung disease
NCT ID NCT07343661
First seen Jan 15, 2026 · Last updated May 13, 2026 · Updated 19 times
Summary
This study looks for proteins in blood, saliva, and sputum that can show organ damage and predict how well patients with EGPA (a rare inflammatory disease) or severe asthma respond to the drug mepolizumab. Researchers will analyze samples from 90 participants before and after starting treatment. The goal is to find simpler, less invasive ways to monitor disease and tailor therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Policlinico Duilio Casula AOU Cagliari
Cagliari, Cagliari, Italy
Conditions
Explore the condition pages connected to this study.